Revive Therapeutics collaborates with University of Health Sciences Antigua to pioneer clinical development of psychedelics

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) is partnering with the University of Health Sciences Antigua (UHSA) to collaborate on utilizing the company’s novel psychedelic-assisted therapies and pioneering the clinical research and development of psychedelics in Antigua and Barbuda.  “We are excited to partner with UHSA as the relationship complements and accelerates our research and commercial goals with psychedelics and advances our patented drug delivery technology to deliver psychedelics in an oral thin film patch and topical forms in human clinical studies to support regulatory approvals globally,” said Derrick Welsh, COO of Psilocin Pharma, a division of Revive.  Dr Adedayo Akande, president of UHSA, said that through its partnership with Revive, the school has the opportunity to become a regional leader in the research of psychoactive therapies for mental health.  READ: Revive Therapeutics partners with India-based specialty pharma Supriya Lifescience to advance Bucillamine to treat coronavirus “Our medical students will now have access to the scientific knowledge and uses of treatments long before joining the physician workforce, which is a great benefit. We too are excited to partner with Revive as we contribute to the future of medicine,” Dr Akande added. In a statement, as part of the proposed collaboration, Revive said it and UHSA seek to accomplish the following activities: Development of a Psychedelic treatment center in Antigua and Barbuda using Revive’s novel formulations and delivery forms of psychedelics, including its proprietary psilocybin oral-thin film product to treat mental health and substance abuse disorders; Research on UHSA’s campus will exclusively use Revive’s intellectual property, developed at the University of Wisconsin-Madison, with the aim to be the foundation for novel psychedelic therapies for research and commercial use in Antigua and Barbuda; Conduct clinical studies to support regulatory drug approvals in the Caribbean and to accelerate US Food and Drug Administration clinical development plans; and Establishment of a Master’s in Psychedelic Medicine for Doctor of Medicine students and for those seeking to expand their knowledge of the field of psychedelic medicine. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham